A supplier may pass an initial audit, provide the requested documentation, and earn a place on an approved supplier list. That approval is an important milestone, but it does not tell you how the supplier will perform six months later, after a process change, a staffing transition, or a rise in production volume.
For life sciences organizations, supplier qualification works best as an ongoing process. The goal is to understand the risks a supplier introduces, define how those risks will be controlled, and recognize when performance calls for a closer look.
Start with the impact on product quality
Every supplier relationship does not require the same level of oversight. A supplier providing a critical component, performing contract manufacturing, or generating data used in a quality decision presents a different risk than a supplier whose work has no direct effect on the product.
Before setting oversight activities, consider what the supplier provides, how a failure could affect quality or patients, and whether your organization could detect that failure before the product moves forward. Those answers can guide the depth of an initial assessment, the frequency of reviews, and the triggers for reassessment.
A risk-based approach also helps teams spend their time where it matters most. It gives quality, procurement, and operations a shared reason for the controls they choose.
Define responsibilities before work begins
Unclear ownership can turn a manageable issue into a prolonged investigation. Who reviews a deviation? Who approves a proposed process change? When must the supplier notify your team? Who determines whether an affected lot can be used?
For contract drug manufacturing, FDA guidance recommends a written quality agreement that describes each party’s CGMP related roles and responsibilities. The agreement should reflect how the work will be performed and how the organizations will communicate when something changes. A signed document alone cannot replace effective oversight.
The details will vary by supplier and product, but the principle is consistent: your team should know who is responsible for each quality decision before that decision becomes urgent.
Watch performance between audits
An audit offers a view of a supplier at a particular point in time. Routine performance data can reveal what happens afterward.
Late or incomplete deviation reports, recurring material defects, missed change notifications, and repeated delivery problems can each signal a need to investigate. The value comes from reviewing these signals together and asking whether they point to an isolated event or a weakening process.
For example, a single late shipment may be a logistical problem. Repeated delays paired with documentation errors could warrant a broader conversation about capacity, staffing, or process control. Your monitoring program should make it possible to spot that pattern and document what your team did in response.
Make changes a reason to reassess
A supplier that was suitable when approved may introduce new risks after moving a manufacturing site, changing a key process, replacing a subcontractor, or significantly increasing output. Your organization may also change the way it uses the supplied material or service.
Supplier change notification requirements should be clear, and incoming changes should receive a documented impact assessment. Depending on the change, that assessment might lead to additional testing, an updated agreement, a targeted audit, or a new qualification activity. The decision should follow the potential impact, not a fixed checklist applied to every change.
Connect supplier issues to the quality system
Supplier oversight should feed into deviation management, CAPA, change control, and management review where appropriate. If an investigation identifies a supplier related cause, closing the internal record without checking the supplier’s corrective action can leave the problem unresolved.
The same applies in the other direction. A recurring supplier issue may reveal a weakness in your own specifications, incoming controls, or communication process. Effective oversight asks what both organizations need to improve.
FDA’s current medical device Quality Management System Regulation incorporates ISO 13485:2016 as the foundational quality system framework, reinforcing the need for manufacturers to manage quality and risk across their operations. The specific requirements and controls should be evaluated for the products and activities involved.
Build a program you can explain
A strong supplier program should let your team answer a few straightforward questions: Why was this supplier approved? What risks were identified? How is performance monitored? What changed since approval? And what action did the organization take when concerns appeared?
When those answers are supported by current records and clear decisions, supplier qualification becomes more than an onboarding task. It becomes a practical way to protect product quality as relationships and operations evolve.
Need to strengthen your supplier qualification or oversight program? EMMA International can help assess gaps, clarify quality responsibilities, and build processes that support consistent, risk-based decisions. Contact our team.
